Kowa obtains approval from MHLW for Rho kinase inhibitor as ocular hypertension therapeutic

In clinical trials with Japanese patients suffering from ocular hypertension and primary open-angle glaucoma, this agent was used in combination with existing therapies or alone. In any case, it showed effects in intraocular pressure reduction.

Kowa press release, Sept. 29, 2014

Most popular posts: